Biogen Inc (NASDAQ:BIIB)
| 299.35 BATS BZX Real-Time Price As of 10:41am ET |  -3.08 / -1.02%Today’s Change | 188.54 Today|||52-Week Range 319.74 | +8.10% Year-to-Date |
Latest BIIB News | Press Releases
| Cassava (SAVA) Up on Progress With Alzheimers Disease Study May 30 / Zacks.com - Paid Partner Content | Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue? May 25 / Zacks.com - Paid Partner Content |
| Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue? May 26 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 302.43 |
| Today’s open | 302.97 |
| Day’s range | 298.23 - 302.97 |
| Volume | 9,267 |
| Average volume (3 months) | 908,413 |
| Market cap | $43.2B |
Data as of 10:41am ET, 06/02/2023
Growth & Valuation
| Earnings growth (last year) | +100.92% |
| Earnings growth (this year) | -12.58% |
| Earnings growth (next 5 years) | +5.76% |
| Revenue growth (last year) | -9.32% |
| P/E ratio | 13.9 |
| Price/Sales | 4.29 |
| Price/Book | 3.21 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRNAModerna Inc | +1.29 | +1.00% |
| ILMNIllumina Inc | +2.32 | +1.17% |
| ---- | ||
| BMRNBiomarin Pharmaceuti... | +2.59 | +2.94% |
Data as of 10:42am ET, 06/02/2023
Financials
| Next reporting date | July 25, 2023 |
| EPS forecast (this quarter) | $3.75 |
| Annual revenue (last year) | $9.4B |
| Annual profit (last year) | $3.0B |
| Net profit margin | 32.30% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
